Domestic Chinese travel has recovered to levels seen before COVID. A recovery of Asian travel is likely to follow. Two stocks stand to revalue on an increase in mobility trends.
A very early stage biotech opportunity with links to big pharma. We are seeing small scattered call buying today.
Back in September, we mentioned this stock on news about its partnership with Microsoft. Since then it has pulled back mainly due to rotation from Growth to Value. We believe it has now bottomed and presenting a buying opportunity.
December is now the number three S&P 500 and Dow Jones Industrials month since 1950, averaging gains of 1.5% on each index.
This early stage media company sells at 20% percent discounted valuation to Netflix. It has double the revenue growth, higher margins and its service is only priced at $15/year!
JP Morgan says COVID distribution is likely to positive affect a value stock in the healthcare sector. We outline how to take advantage of this.
A leader in streaming media recently increased monthly subscription pricing. Will there be a spike in the churn rate in Q4? We present a bullish case for the stock with a clear price target.
The MACD indicators applied to DJIA, S&P 500 and NASDAQ are all positive as of today’s close. These leads to several buy signals across various equity indexes, according to the seasonal investment strategy.
If COVID cases continue to rise this winter, this stock stands to gain. Currently, revenue growth rates exceed 100% year over year.
Reliance on coal for energy in the US continues to fall, even under the Trump administration. Solar power is on the rise. As the US market pulls back, US tech stocks underwhelming guidance is likely misleading.